Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Apr 7, 2020; 26(13): 1501-1512
Published online Apr 7, 2020. doi: 10.3748/wjg.v26.i13.1501
Table 3 Univariate analysis in the validation cohort
VariablesOverall survival
Recurrence-free survival
HR95%CIP valueHR95%CIP value
Age0.9960.981-1.0110.5940.9900.976-1.0040.148
Gender, F/M0.9070.667-1.2330.5340.9200.695-1.2180.560
HBsAg1.0040.717-1.4050.9821.1100.819-1.5050.500
Hepatolithiasis1.0920.744-1.6020.6540.7990.551-1.1580.236
Child-Pugh grade, A /B0.8520.435-1.6710.6420.7510.418-1.3500.339
Ascites1.4400.871-2.3820.1551.5801.004-2.4870.048a
CA-199, ≥ 22/< 221.7441.390-2.188< 0.001a1.4021.140-1.7220.001a
Tumor size1.0540.997-1.1150.064a1.0841.030-1.1410.002a
Tumor number, Multiple/Single1.8451.344-2.531< 0.001a1.8741.397-2.513< 0.001a
Tumor differentiation, Moderate-Poor/Well13.4491.881-96.1500.0106.0531.930-18.9820.002a
Macrovascular invasion1.0500.730-1.5110.7921.0090.718-1.4180.959
Microvascular invasion1.9951.228-3.2420.005a2.0231.290-3.1720.002a
Liver capsule invasion1.5531.118-2.1590.009a1.2800.955-1.7160.099a
Node-positive2.0091.438-2.808< 0.001a1.5251.115-2.0850.008a
Perineural invasion1.3660.906-2.0590.1361.2620.867-1.8380.225
Cirrhosis0.9840.686-1.4120.9321.0540.762-1.4590.749
TNM stage, III/I-II1.7741.242-2.5330.002a1.4131.035-1.9290.029
BCLC, B-C/0-A1.6191.136-2.3080.008a1.8491.335-2.562< 0.001a
NLR, > 2.62/≤ 2.621.6491.202-2.2610.002a1.6351.226-2.1800.001a
PLR, > 103/≤ 1031.4171.036-1.9380.029a1.0650.803-1.4140.661
GLR, > 33.7/≤ 33.71.8261.300-2.5650.001a1.7801.315-2.408< 0.001a